Neutralizing antibodies targeting SARS-CoV-2 spike protein

Area of Science:

• Virology
• Immunology
• Therapeutics

Background:

• The SARS-CoV-2 pandemic has caused unprecedented global disruption.
• Urgent need for effective prophylactic and therapeutic strategies against the virus.
• Development of neutralizing antibodies is a key focus for pandemic control.

Purpose of the Study:

• To review and summarize the progress in the identification and development of neutralizing antibodies against SARS-CoV-2.
• To analyze the epitopes targeted by these antibodies and their germline origins.
• To provide insights for future COVID-19 treatment and vaccine design.

Main Methods:

• Comprehensive review of dozens of studies on anti-spike antibodies.
• Analysis of antibody identification approaches, including B cell screening and recombinant libraries.
• Examination of antibody epitope mapping and germline gene usage.

Main Results:

• Promising therapeutic antibodies are identified through diverse methods like B cell screening and immunized animal models.
• Antibody targets (epitopes) are primarily the Receptor Binding Domain (RBD) of the spike protein, but also non-RBD sites, not necessarily overlapping with ACE2 binding.
• Effective neutralizing antibodies show convergence towards specific germline genes (e.g., IGHV3-30, IGHV3-53, IGHV3-66) with varying somatic mutations.

Conclusions:

• Significant progress has been made in developing neutralizing antibodies for SARS-CoV-2.
• Understanding epitope targets and germline gene enrichment is crucial for optimizing antibody therapeutics.
• This review offers valuable information for advancing COVID-19 treatment strategies and vaccine development.